Elagolix - Abbvie/Neurocrine

Drug Profile

Elagolix - Abbvie/Neurocrine

Alternative Names: ABT-620; Elagolix sodium; NBI-56418

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Endometriosis
  • Phase III Uterine leiomyoma
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 13 Mar 2018 Positive top-line efficacy and adverse events data from the phase III ELARIS UF-II trial in Uterine leiomyoma released by AbbVie
  • 21 Feb 2018 Positive top-line efficacy and adverse events data from the phase III ELARIS UF-I trial in Uterine leiomyoma released by AbbVie
  • 28 Dec 2017 AbbVie initiates enrolment in a phase III trial for Endometriosis (Monotherapy, Combination therapy) in USA (NCT03343067)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top